Teknova reports FY2024 revenue $37.7M (+3% YoY), guides FY2025 $39-42M, amends credit facility

Alpha Teknova, Inc.

FY2024 revenue $37.7M (+3% YoY); Q4 revenue $9.3M (+18% YoY). Clinical Solutions Q4 revenue $1.85M (+110% YoY).
Net loss FY2024 $26.7M ($0.57/share) vs $36.8M ($1.16) in FY2023; adjusted EBITDA -$14.5M vs -$19.8M.
2025 guidance: revenue $39-42M, free cash outflow <$12M (vs -$13.5M in FY2024).
New $28.245M credit facility ($23.245M term + $5M revolver), maturity March 2030, principal pay starting April 2028.
Covenants: minimum net revenue $39M for TTM ending Dec 2025; minimum cash $8M.

item 1.01 item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-031995
form_type: 8-K
ticker: TKNO
cik: 0001850902
company_name: Alpha Teknova, Inc.
filed_at: 2025-03-04T23:59:59+00:00
discovered_at: 2026-05-14T18:03:05.299428+00:00
generated_at: 2026-05-25T15:29:57.292861+00:00
sec_items: ["1.01", "2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-031995
json_url: https://secwatch.observer/filing/0000950170-25-031995.json
markdown_url: https://secwatch.observer/filing/0000950170-25-031995.md
text_url: https://secwatch.observer/filing/0000950170-25-031995.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1850902/000095017025031995/0000950170-25-031995-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1850902/000095017025031995/tkno-20250304.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-031995

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.